Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) was upgraded by investment analysts at Vetr from a “strong sell” rating to a “sell” rating in a research report issued on Monday. The firm currently has a $12.46 price target on the specialty pharmaceutical company’s stock. Vetr‘s price objective would indicate a potential downside of 9.51% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the company. Guggenheim initiated coverage on Valeant Pharmaceuticals International in a report on Saturday, June 17th. They issued a “buy” rating and a $18.00 price objective for the company. BidaskClub upgraded Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating in a report on Thursday, June 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, June 30th. Jefferies Group LLC reiterated a “buy” rating and issued a $18.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, July 14th. Finally, Cantor Fitzgerald set a $23.00 price objective on Valeant Pharmaceuticals International and gave the company a “buy” rating in a report on Friday, July 28th. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $17.62.

Valeant Pharmaceuticals International (VRX) opened at 13.77 on Monday. The company has a 50 day moving average price of $14.22 and a 200-day moving average price of $13.18. Valeant Pharmaceuticals International has a 52-week low of $8.31 and a 52-week high of $27.84. The firm’s market cap is $4.80 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $0.97 by $0.08. The business had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The firm’s revenue was down 7.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.88) earnings per share. Equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/20/valeant-pharmaceuticals-international-inc-vrx-rating-increased-to-sell-at-vetr-inc.html.

In related news, Director Schutter Richard U. De purchased 10,000 shares of Valeant Pharmaceuticals International stock in a transaction that occurred on Monday, August 21st. The stock was purchased at an average cost of $14.33 per share, with a total value of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 5.87% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. ValueAct Holdings L.P. boosted its position in Valeant Pharmaceuticals International by 20.0% during the first quarter. ValueAct Holdings L.P. now owns 17,997,224 shares of the specialty pharmaceutical company’s stock valued at $198,509,000 after purchasing an additional 3,002,963 shares during the last quarter. Vanguard Group Inc. boosted its position in Valeant Pharmaceuticals International by 4.2% during the second quarter. Vanguard Group Inc. now owns 7,274,717 shares of the specialty pharmaceutical company’s stock valued at $125,853,000 after purchasing an additional 294,643 shares during the last quarter. Bank of Montreal Can boosted its position in Valeant Pharmaceuticals International by 9.8% during the second quarter. Bank of Montreal Can now owns 6,330,670 shares of the specialty pharmaceutical company’s stock valued at $109,521,000 after purchasing an additional 564,215 shares during the last quarter. OppenheimerFunds Inc. boosted its position in Valeant Pharmaceuticals International by 17.1% during the first quarter. OppenheimerFunds Inc. now owns 4,489,169 shares of the specialty pharmaceutical company’s stock valued at $49,516,000 after purchasing an additional 656,116 shares during the last quarter. Finally, CIBC World Markets Inc. boosted its position in Valeant Pharmaceuticals International by 2.3% during the second quarter. CIBC World Markets Inc. now owns 3,741,413 shares of the specialty pharmaceutical company’s stock valued at $64,726,000 after purchasing an additional 83,592 shares during the last quarter. 50.47% of the stock is owned by hedge funds and other institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.